Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Ferrer Internacional S.A.

Home Clinical Trial Sponsors and OrganizationsFerrer Internacional S.A.

Ferrer Internacional S.A.

Av Quilin 5273, Santiago, Chile

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

62

37 active

Approvals

187

Total approvals

Agencies

6

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

29

46.8%

Phase 3

9

14.5%

Phase 2

7

11.3%

Phase 4

6

9.7%

Trial Status Distribution

Active, not recruiting

37

59.7%

Available

1

1.6%

Completed

12

19.4%

Recruiting

2

3.2%

Terminated

7

11.3%

Unknown

2

3.2%

Withdrawn

1

1.6%

Clinical Trials

Trials sponsored by this organization (62)

Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness

Feb 202560 participants

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Active, not recruiting

Jul 2024241 participants

OPEN LABEL, FOUR-PERIOD, TWO-SEQUENCE, FULLY-REPLICATED, RANDOMIZED, SINGLE DOSE COMPARATIVE STUDY TO ASSESS BIOEQUIVALENCE OF Polypill AAR 100/80/10 mg capsules FIXED DOSE COMBINATION (TEST) VERSUS EQUAL DOSES OF COADMINISTERED Aspirin® N 100mg tablets + Cardyl® 80mg film-coated tablets + Acovil® 10mg tablets (REFERENCE formulations) IN HEALTHY MALE AND FEMALE VOLUNTEERS UNDER FASTING CONDITIONS

Active, not recruiting

Jul 202356 participants

A study to investigate the safety of FAB122 in patients with Amyotrophic Lateral Sclerosis on the long term.

Active, not recruiting

Mar 2023225 participants

Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

Mar 2023201 participants

A study to investigate the safety of FAB122 in patients with Amyotrophic Lateral Sclerosis on the long term.

Active, not recruiting

Dec 2022225 participants

A study to investigate the safety of FAB122 in patients with Amyotrophic Lateral Sclerosis on the long term.

Active, not recruiting

Dec 2022225 participants

A study to investigate the safety of FAB122 in patients with Amyotrophic Lateral Sclerosis on the long term.

Active, not recruiting

Nov 2022225 participants

Page 1 of 8

Approvals

Approvals by Agency

EMA

European Medicines Agency

1

Approvals

CANADA

Health Canada

1

Approvals

PHILIPPINES

Philippines FDA

6

Approvals

SFDA

Saudi Food and Drug Authority

1

Approvals

NPRA

National Pharmaceutical Regulatory Agency

1

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

177

Approvals

Recent Approvals

GAMALATE B (6) SOLUCION ORAL

Zalain® Cream (Sertaconazole nitrate 2%)

CAFERGOT 1 mg/100 mg COMPRIMIDOS

GELODROX SUSPENSION ORAL

DOLOCATIL 500 mg COMPRIMIDOS

DOLOCATIL CODEINA 500/15 mg COMPRIMIDOS

PSICO SOMA LIQUIDO

TOFRANIL 10 mg COMPRIMIDOS RECIBIERTOS

PANTOMICINA 250 mg GRANULADO PARA SUSPENSION ORAL EN SOBRES

News

Pelthos Therapeutics Acquires Xepi for Antibiotic-Resistant Impetigo Treatment and Secures $18 Million Financing

- Pelthos Therapeutics acquired U.S. commercialization rights to Xepi (ozenoxacin) cream, the first new impetigo treatment approved in over 10 years, addressing critical antibiotic resistance issues. - The FDA-approved topical antimicrobial targets impetigo caused by Staphylococcus aureus and Streptococcus pyogenes, affecting approximately 3 million Americans annually, primarily children ages 2-5. - The company secured $18 million in convertible notes financing to support Xepi's re-launch in late 2026 and accelerate commercialization of its molluscum contagiosum treatment ZELSUVMI. - Xepi represents a significant therapeutic advancement as one of few treatments effective against both methicillin-resistant and mupirocin-resistant Staphylococcus aureus infections.

On this page

Overview
Clinical Trials62
Approvals187
News1

Back to Organizations